Combined Tumor and Immune Signals From Genomes or Transcriptomes Predict Outcomes of Checkpoint Inhibition in Melanoma
Demographics (2)
- age - Subject age (phv00495082.v1.p1)
- sex - Gender of participant (phv00495075.v1.p1)
Disease Events (5)
- AFFECTION_STATUS - Case control status of the subject for Melanoma; all subjects are patients. (phv00495083.v1.p1)
- HISTOLOGICAL_TYPE - Sample histology (phv00495088.v1.p1)
- IS_TUMOR - Sample represents a tumor sample or not (phv00495087.v1.p1)
- TUMOR_STAGE - Tumor stage of sample (phv00495090.v1.p1)
- TUMOR_TREATMENT - Tumor treatment (phv00495091.v1.p1)
Race and Ethnicity (1)
- race - Race of participant (phv00495081.v1.p1)
Other (12)
- ANALYTE_TYPE - Analyte type (phv00495086.v1.p1)
- BODY_SITE - Location from where sample was obtained (phv00495085.v1.p1)
- CONSENT - Consent group for data-sharing (phv00495074.v1.p1)
- PRIMARY_TUMOR_LOCATION - Sample taken from primary tumor (phv00495089.v1.p1)
- SAMPLE_ID - Sample ID (phv00495084.v1.p1)
- SAMPLE_ID - Sample ID (phv00495079.v1.p1)
- SEQUENCING_CENTER - Sequencing center (phv00495092.v1.p1)
- SOURCE_SUBJECT_ID - Subject ID used in the Source Repository (phv00495077.v1.p1)
- SUBJECT_ID - Subject ID (phv00495073.v1.p1)
- SUBJECT_ID - De-identified Subject ID (phv00495080.v1.p1)
- SUBJECT_ID - Subject ID (phv00495078.v1.p1)
- SUBJECT_SOURCE - Source repository where subjects originate (phv00495076.v1.p1)